GlassScriptPhysician profile
Dina Liberman
NPI 1417986878
$33,853.08
in general payments reported to CMS, 2019-2025
47 companies · $4,461 in 2025
The $4,461 reported for 2025 was more than what 85% of Allergy & Immunology (Internal Medicine) providers received nationally (typical 2025 total: $681).
See the full distribution for Allergy & Immunology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,805 · 2020: $3,302 · 2021: $4,192 · 2022: $5,351 · 2023: $4,888 · 2024: $4,853 · 2025: $4,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,194.37 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $7,434.58 | 2019-2025 | |
| Amgen INC. | $5,587.88 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $2,858.51 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $2,509.26 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,808.65 | 2019-2025 | Jardiance, Cyltezo |
| Novo Nordisk INC | $1,413.69 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,405.81 | 2019-2025 | Jardiance, Mounjaro |
| Amarin Pharma, INC. | $1,075.02 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $803.22 | 2019-2025 | Xifaxan, Trulance |
| Scilex Pharmaceuticals INC. | $706.09 | 2019-2025 | Ztlido |
| Novartis Pharmaceuticals Corporation | $665.36 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $663.59 | 2023-2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $649.08 | 2019-2024 | Camzyos, Eliquis |
| Pfizer INC. | $620.62 | 2019-2025 | |
| Allergan, INC. | $568.49 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dina Liberman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.